Business
Alar Announced Buprenorphine Injectable, ALA-1000, Demonstrated Long-Term Efficacy and Favorable Safety Profile in Canine Osteoarthritis Pain Management
Alar Pharmaceuticals Inc. (Alar, TPEx:6785), a clinical-stage biopharmaceutical company focused on developing long-acting injectables (LAIs), announces the completion and positive results of ALA-1000 study in client-owned dogs with osteoarthritis. The results demonstrate the efficacy, safety, tolerability, and pharmacokinetic (PK) durability for ALA-1000, a subcutaneous buprenorphine LAI, at target dose in dogs with osteoarthritis-associated pain.
About this update from Alar Pharmaceuticals Inc
[{"type":"list","items":[{"val":[{"type":"text","content":"A study in client-owned dogs with osteoarthritis demonstrated that a single injection of ALA-1000 effectively mitigates pain and improves functional mobility, with a sustained drug release profile for at least 1 month. The study also confirmed a favorable safety profile with repeated use, particularly within the geriatric population.","length":335,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":335,"olType":false},{"type":"text","content":"TAICHUNG, March 16, 2026 /PRNewswire/ -- Alar Pharmaceuticals Inc. (Alar, TPEx:6785), a clinical-stage biopharmaceutical company focused on developing long-acting injectables (LAIs), announces the completion and positive results of ALA-1000 study in client-owned dogs with osteoarthritis. The results demonstrate the efficacy, safety, tolerability, and pharmacokinetic (PK) durability for ALA-1000, a subcutaneous buprenorphine LAI, at target dose in dogs with osteoarthritis-associated pain.","length":492,"tagName":"p"},{"type":"text","content":"The primary endpoint was based on the owner-rated Canine Brief Pain Inventory (CBPI) questionnaire, which evaluates pain severity, its impact on dogs' daily mobility, and overall quality of life. Secondary endpoint included veterinarian-assessed lameness scoring for evaluating lameness, pain on manipulation, range of motion, and joint swelling. The study results revealed that a single injection of ALA-1000 produced a remarkably high treatment success rate (≥75%) at Day 28 across dogs with varying baseline pain severity, as assessed by either CBPI or lameness scoring. Treatment success was defined as a ≥1-point reduction in pain severity score and ≥2-point reduction in pain interference score on the CBPI, or a ≥1-point reduction in lameness or ≥2-point reduction in total score on the lameness scoring. Moreover, in dogs receiving continuous monthly dosing of ALA-1000 for more than 1 year, no evidence of tolerance was observed based on efficacy assessments.","length":972,"tagName":"p"},{"type":"text","content":"ALA-1000 demonstrated a well-tolerated safety profile at target dose, particularly within the geriatric dog population. No drug-related injection site reactions, including redness, swelling, or irritation were observed given the minimal injection volume.","length":254,"tagName":"p"},{"type":"text","cont...